Areas of Focus
- Development of new generation CAR-T technology using novel gene editing tools
- Identification and development of new therapies to enhance CAR-T cell function using novel screening methods
- Development of new generation immune cell therapy techniques using synthetic biology methods
Work Experience
- 2022-present: East China Normal University, Researcher
- 2016-2022: East China Normal University, Associate Researcher
- 2012-2016: Shanghai Cancer Institute, Assistant Researcher
Academic Background & Achievements
- 2007-2012 PhD: East China Normal University
- 2009-2010 Joint Training: Beijing Institute of Life Sciences
- 2003-2007 Bachelor's Degree: Tongji University
Publications
- Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL, Jiqin Zhang et al., 2022
- Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study, Jiqin Zhang et al., 2023
- Intelligent tunable CAR-T cell therapy leads the new trend, Jiqin Zhang et al., 2023
- Let's turn the CAR-T cells ON and OFF precisely, Jiqin Zhang et al., 2022
- Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation, Jiqin Zhang et al., 2019
- EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer, Jiqin Zhang et al., 2017
- Dysregulated DNA methyltransferase 3A upregulates IGFBP5 to suppress trophoblast cell migration and invasion in preeclampsia, Jiqin Zhang et al., 2017
- EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1, Jiqin Zhang et al., 2016
- Dissecting the precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in mammals, Jiqin Zhang et al., 2016
- Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability, Jiqin Zhang et al., 2016
- S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance, Jiqin Zhang et al., 2011
- Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex, Jiqin Zhang et al., 2023
- Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies, Jiqin Zhang et al., 2022
- Induction of TGF-β receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia, Jiqin Zhang et al., 2020
- UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β-catenin signaling, Jiqin Zhang et al., 2020
- Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants, Jiqin Zhang et al., 2018
- Cas9-nickase–mediated genome editing corrects hereditary tyrosinemia in rats, Jiqin Zhang et al., 2018
- A fusion receptor as a safety switch, detection, and purification biomarker for adoptive transferred T cells, Jiqin Zhang et al., 2017
- Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN–glioblastoma in vivo, Jiqin Zhang et al., 2016
- Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12, Jiqin Zhang et al., 2015
- The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III, Jiqin Zhang et al., 2014
- A novel EGFR isoform confers increased invasiveness to cancer cells, Jiqin Zhang et al., 2013
- UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9, Jiqin Zhang et al., 2013
- An elaborate regulation of mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors, Jiqin Zhang et al., 2012
- Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice, Jiqin Zhang et al., 2012
Awards
- 2023: National Natural Science Foundation of China Outstanding Young Scientist
- 2022: Zijiang Outstanding Young Scholar, East China Normal University
- 2023: Top 10 Research Progress in Hematology in China, Development and clinical application of non-viral targeted integration CAR-T technology
- 2023: Important Medical Progress in China 2022, Development of a new generation of CAR-T technology to improve the remission rate of treatment for relapsed refractory non-Hodgkin's lymphoma
- 2022: Science and Technology Achievement Transformation Contribution Award, Southern Weekend
